40 results about "Clinical course" patented technology

A role of the human PDE4D gene in stroke is disclosed. Methods for diagnosis, prediction of clinical course and treatment for stroke using polymorphisms in the PDE4D gene are also disclosed.

The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D using polymorphisms in the T2D risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D.

A role of the human EXT2 gene in metabolic conditions such as T2D is disclosed. Methods and test kits for diagnosis, T2D risk prediction and prediction of clinical course of a metabolic condition using biomarkers related to the EXT2 gene are disclosed. Novel methods for prevention and treatment of metabolic diseases based on EXT2 gene, polypeptides and EXT2 related pathways are also disclosed.

This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (ALL). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with ALL based on patterns of surface marker expression unique to ALL.

Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.

A system, method, and apparatus for a patient simulator that interacts with a diagnostic or therapeutic medical device. The system includes a computing device coupled to a patient module. The patient module includes hydraulic equipment that simulates a baseline fluid interconnection with a therapeutic device. The computing device manages physical and virtual data, provides algorithmic calculations for simulating hypothetical patient vital signs, long-term clinical course, and simulates related fluid properties. The simulation system automatically executes a step-wise clinical scenario, specified in a spreadsheet format of patient conditions and equipment scenarios, that also includes audio/visual stimuli of operating room and diagnostic clinic environments, along with data recording capabilities. The therapeutic device can be a heart lung machine (HLM), an extracorporeal membrane oxygenation (ECMO) machine, an emergency cardiac life support (ECLS) device, a ventricular assist device (VAD), a dialysis machines, a hyperthermic intraperitoneal chemotherapy (HIPEC) machine, and an aortic balloon pump.

A role of the human PDE4D gene in stroke is disclosed. Methods for diagnosis, prediction of clinical course and treatment for stroke using polymorphisms in the PDE4D gene are also disclosed.

A system, a method, and an apparatus for a patient simulator that interacts with a diagnostic or therapeutic medical device. The system includes a computing device coupled to a patient module. The patient module includes hydraulic equipment that simulates a baseline fluid interconnection with a therapeutic device. The computing device manages physical and virtual data, provides algorithmic calculations for simulating hypothetical patient vital signs, long-term clinical course, and simulates related fluid properties. The simulation system automatically executes a step-wise clinical scenario, specified in a spreadsheet format of patient conditions and equipment scenarios, that also includes audio/visual stimuli of operating room and diagnostic clinic environments, along with data recording capabilities. The therapeutic device can be a heart lung machine (HLM), an extracorporeal membrane oxygenation (ECMO) machine, an emergency cardiac life support (ECLS) device, a ventricular assist device (VAD), a dialysis machines, a hyperthermic intraperitoneal chemotherapy (HIPEC) machine, and an aortic balloon pump.

Heteroplasmy mitochondrial DNA (mtDNA) markers and haplotypes of susceptibility or predisposition to atherosclerosis, coronary heart disease (CHD) and subdiagnosis of atherosclerosis and CHD and related medical conditions are disclosed. The biomarkers may be selected from the following heteroplasmy makers: 652lns/del G; A1555G; C3256T; T3336C; G12315A; G13513A; G14459A; G14846A; G15059A. Methods and kits for diagnosis, subdiagnosis, and prediction of clinical course and efficacy of treatments for CHD, atherosclerosis and related phenotypes using heteroplasmy in the risk genes and loci and other related biomarkers are thus provided. Novel methods for prevention and treatment of atherosclerosis, CHD and related conditions based on the disclosed CHD genes, loci, polypeptides and related pathways are also provided.

Genes, SNP markers and haplotypes of susceptibility or predisposition to hypertension (HT) are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for HT using polymorphisms in the HT risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of HT. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of HT.

Genes, SNP markers and haplotypes of susceptibility or predisposition to CHD such as AMI are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for AMI using polymorphisms in the AMI risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of AMI and CHD. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of CHD and AMI.

The method and the kit are useful as tools for classifying a patient diagnosed with mantle cell lymphoma into the category of: indolent or conventional. The method comprises: a) providing a sample from a patient suffering from mantle cell lymphoma; b) determining the level of expression of at least one gene selected from the group consisting of: RNGTT, HDGFRP3, FARP1, HMGB3, LGALS3BP, PON2, CDK2AP1, DBN1, CNR1, CNN3, SOX11, SETMAR and CSNK1E in said sample; and c) comparing the level of expression of each of the measured genes with respect to the level of expression of the same genes in a control sample; wherein the absence of expression or the underexpression of said genes with respect to the same genes in said control sample is indicative of the indolent clinical course of the MCL.

An electronic system generates and manages multiple knowledge bases of medical students and practitioners. The knowledge bases are organized according to and for the function of specific limited medical problems. Data regarding each problem cross-references both basic sciences and clinical courses. Users are able to create their own knowledge base with the use of teaching data, their own user generated data, and third party user generated data. Data is dynamically updated, and the knowledge bases support the future medical practice of students.

The present invention provides a method of diagnosing a mylodysplastic syndrome, a method of ascertaining the clinical course of a myelodysplastic syndrome or a method of ascertaining response to a therapy regimen in a subject diagnosed with a myelodysplastic syndrome, and kits for effecting the same.

The present disclosure describes a system and method for visualizing clinical data. The system can display multiple kinds of clinical data in a timeline format. Further, the system can provide a user with a holistic view of a subject's health.

The present invention provides that Ras-like, estrogen-regulated, growth inhibitor (RERG) is a malignant mesothelioma biomarker of clinical course and treatment sensitivity and, itself a target for mesothelioma treatment. A low RERG level in a mesothelioma subject indicates poor prognosis. Analyzing RERG expression level along can help mesothelioma patients make treatment choices. Furthermore, mesothelioma can be treated by modulating RERG activity, for example, with treatment with estrogen or estrogen-like agents.

A system, non-transitory computer readable medium, and method are provided for determining patient care services for a patient being treated for a life-threatening or life-limiting progressive illness. Patient symptoms are identified by receiving data comprising personal health information of a patient. The level of distress of the patient is determined by analyzing the data comprising personal health information of the patent. A score is established based on criteria comprising the level of distress of the patient and a severity of the patient symptoms. The score correlates the level of distress of the patient with a clinical course of the life-threatening or life-limiting progressive illness. One or more patient care services appropriate for the clinical course of the life-threatening or life-limiting progressive illness and the level of distress of the patient is determined based on the score.

The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.

Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells (HSC). Clinical course of MDS can be divided into several stages; an indolent chronic phase termed “refractory anemia (RA)” or “RA with ringed sideroblasts”, and advanced stages including “RA with excess of blasts (RAEB)” and MDS-associated leukemia. Despite a relatively high incidence of MDS, there are few effective means to treat individuals at its advanced stages. DNA microarray would be a useful tool to clarify the molecular pathogenesis of, and to develop novel treatments against, MDS. However, a simple comparison with DNA microarray of bone marrow (BM) mononuclear cells from individuals at distinct stages of MDS would mainly lead to the identification of “pseudo-positive” genes whose expression alterations only reflect the difference in the proportion of MDS blasts within BM. To efficiently analyze the stage-progression mechanism in MDS, AC133 cell surface marker-positive HSC was purified from BM of healthy volunteers as well as 30 MDS patients, and used to compare the expression profiles of 2304 genes by microarray made by the inventor. The inventor succeeded in isolating sets of genes, expression of which was specific to either indolent stage or the advanced ones.

The invention discloses a horse multi-color organ skin-fur-skeleton connected dubbed dry specimen. The specimen comprises a specimen body and a bench for fixing the specimen body; the specimen body ismainly composed of a prosthesis bracket, a skin-fur-skeleton connecting body, an isolated skeleton and an imitated arcus costarum; the isolated skeleton is manufactured on the prosthesis bracket in series, the skin-fur-skeleton connecting body is arranged on the prosthesis bracket through gesture adjustment, and multi-color dry cardiovascular organs, multi-color dry organs of the respiratory tract and multi-color dry organs of the digestive tract are arranged in a body cavity of the specimen body according to original positions and original shapes. According to the specimen, the skin and furof the whole body are connected, the shape is life-like, the dry specimen can have multiple application functions of display of the various multi-color organs of an animal specimen, skin-fur-skeletonconnection, dubbed playback teaching and convenient taking and storage, and can replace animal living bodies for practical teaching of clinical courses and elementary courses of animal husbandry and medical science.

The invention relates to the field of biotechnology and medical diagnosis, in particular to application of a set of pathogenic gene mutation sites associated with CP, and application of the gene mutation sites in preparation of a reagent or kit for diagnosing or treating CP and evaluating prognosis. The application of a set of the gene mutation sites in the preparation of the reagent or the kit for diagnosing CP and evaluating the prognosis disclosed by the invention has the advantages of finding the names and frequency of six common pathogenic mutations of CP in China, and having the total carrying frequency as high as 46.1%, and the invention further discloses that the pathogenic mutations have the effect of accelerating the occurrence and progression speed of CP clinical course to provide a scientific basis for the next clinical early diagnosis and making of individualized therapeutic schemes.